Lancet: The long-acting Cabotwe-Lipivirin treatment program, which is available once every 8 weeks, is used for the treatment of people living with HIV

In previous Phase III ATLAS clinical studies, kabotvir-Lippivirin intramuscular injections every 4 weeks were as effective as oral antiviral drugs.
in Phase II clinical and model studies, Cabotwe-Lipivirin therapy, which is performed every 8 weeks, also had better results.
researchers recently compared the anti-HIV-1 effects of kabotwe-Lipivirin treatment every 8 weeks vs 4 weeks.
ATLAS-2M study was conducted in 13 countries, for open, IIIb, non-inferior studies, HIV-1 infected patients received 600mg cabotwe combined 900mg lipivellin or 400mg cabotwe combined 600mg lipivellin every 8 weeks.
48 weeks, the proportion of patients with more than 50 copies of HIV-1 RNA per milliliter of serum, with a non-inferiority boundary of 4%.
1,045 people living with HIV were included in the study, including 522 in the 8-week treatment group and 523 in the 4-week treatment group, of whom 391 were from the ATLAS study (37 percent).
42 years old, 27 percent were women and 73 percent were white.
results showed that the effect of the kabotwe Unilpirin treatment every 8 weeks was comparable to that of 1 treatment every 4 weeks, with 2% and 1% of patients with more than 50 copies of HIV-1 RNA per milliliter of serum.
8 patients (2%) in the 8-week treatment group and 2 patients in the 4-week treatment group (-lt;1%) confirmed the failure of the virological treatment.
safety was similar between groups, with 81% of patients reporting adverse reactions and deaths due to non-treatment.
For people living with HIV-1, the effect of carbotwethy-unileverin treatment is comparable to that of 1 every 4 weeks for people living with HIV-1, and the study supported a long-acting kabotwe-Lippivirin treatment once every 2 months for HIV-1 infections.
。